{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:22Z","timestamp":1792785862317,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Research and Development Center, Dayanand Medical College and Hospital","id":[{"id":"https:\/\/ror.org\/005fgpm31","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>Tofacitinib has emerged as a promising therapy for acute severe ulcerative colitis (ASUC) due to its rapid onset of action. We compared the efficacy and safety of tofacitinib 20\u2009mg\/day vs 30\u2009mg\/day, both administered with intravenous corticosteroids (IVCS), in patients with ASUC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a double-blind, pilot, randomized controlled trial. Adult patients with ASUC were randomized to receive either tofacitinib 20\u2009mg\/day (Group 1) or 30\u2009mg\/day (Group 2) along with IVCS (hydrocortisone, 100\u2009mg IV every 6\u2009hours). The primary endpoint was clinical response by day 7. The secondary outcome was the cumulative probability of medical rescue therapy or post discharge escalation of therapy or colectomy within 90\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-two patients were randomized, with 36 allocated to each treatment group. At day 7, clinical response was achieved in 33\/36 (91.7%) patients in Group 1 and 31\/36 (86.1%) in Group 2(RR 1.06, 95% CI 0.90-1.25; P\u2009=\u2009.46). The absolute difference in response rates was 5.6% (95% CI \u22129.98% to 21.34%). Rescue therapy was required in 3 patients in Group 1 (all received infliximab) and 5 patients in Group 2 (2 underwent colectomy and 3 received infliximab). Event-free survival at 90\u2009days, defined as the absence of rescue therapy, treatment escalation, or colectomy, was similar between groups (83.3% vs 80.2%; log-rank P\u2009=\u2009.74). Adverse events were predominantly mild, with no reported venous thromboembolism or major adverse cardiovascular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this exploratory pilot trial, no statistically significant differences were observed with tofacitinib 30\u2009mg\/day compared with 20\u2009mg\/day when administered with IVCS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration number<\/jats:title>\n                    <jats:p>Clinical Trials Registry-India: CTRI\/2024\/10\/075098<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag147","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:22:17Z","timestamp":1790335337000},"source":"Crossref","is-referenced-by-count":0,"title":["Tofacitinib 20 vs 30 mg in acute severe ulcerative colitis: a\u00a0double-blind randomized controlled trial"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7163-0454","authenticated-orcid":false,"given":"Arshdeep","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9745-1842","authenticated-orcid":false,"given":"Aakash","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-7758","authenticated-orcid":false,"given":"Arshia","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-503X","authenticated-orcid":false,"given":"Dharmatma","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0010-0819","authenticated-orcid":false,"given":"Aman","family":"Thakur","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1198-7215","authenticated-orcid":false,"given":"Lagandeep","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4713-9272","authenticated-orcid":false,"given":"Ankuriti","family":"Singla","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8135-430X","authenticated-orcid":false,"given":"Lavanya","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6726-6151","authenticated-orcid":false,"given":"Ramit","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8867-9526","authenticated-orcid":false,"given":"Varun","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-0988","authenticated-orcid":false,"given":"Omesh","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6097-8172","authenticated-orcid":false,"given":"Yogesh K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4577-1724","authenticated-orcid":false,"given":"Nishant","family":"Sharma","sequence":"additional","affiliation":[{"name":"Dayanand Medical College and Hospital Department of Community Medicine, , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-3969","authenticated-orcid":false,"given":"Vandana","family":"Midha","sequence":"additional","affiliation":[{"name":"Dayanand Medical College and Hospital Department of Internal Medicine, , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6961-6389","authenticated-orcid":false,"given":"Ajit","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"2026101518422828800_jjag147-B1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrgastro.2016.116","article-title":"Acute severe ulcerative colitis: from pathophysiology to clinical management","volume":"13","author":"Hindryckx","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026101518422828800_jjag147-B2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","article-title":"Acute severe ulcerative colitis management: unanswered questions and latest insights","volume":"9","author":"Rivi\u00e8re","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026101518422828800_jjag147-B3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5217\/ir.2024.00189","article-title":"Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India","volume":"24","author":"Singh","year":"2026","journal-title":"Intest Res"},{"key":"2026101518422828800_jjag147-B4","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3390\/jcm11061679","article-title":"Long-term risk of colectomy in patients with severe ulcerative colitis responding to intravenous corticosteroids or infliximab","volume":"11","author":"De Cristofaro","year":"2022","journal-title":"J Clin Med"},{"key":"2026101518422828800_jjag147-B5","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1111\/imj.16074","article-title":"Have changing practices in salvage medical options affected colectomy rates in acute severe ulcerative colitis?","volume":"53","author":"Clark","year":"2023","journal-title":"Intern Med J"},{"key":"2026101518422828800_jjag147-B6","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026101518422828800_jjag147-B7","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026101518422828800_jjag147-B8","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.14309\/ajg.0000000000002674","article-title":"Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience","volume":"119","author":"Berinstein","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026101518422828800_jjag147-B9","doi-asserted-by":"publisher","first-page":"104120","DOI":"10.1016\/j.eclinm.2026.104120","article-title":"Exploring the rationale for upfront corticosteroid\u2013JAK inhibitor combination therapy in acute severe ulcerative colitis","volume":"98","author":"Singh","year":"2026","journal-title":"EClinicalMedicine"},{"key":"2026101518422828800_jjag147-B10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.cgh.2025.07.025","article-title":"Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis","volume":"24","author":"Honap","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026101518422828800_jjag147-B11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5217\/ir.2025.00153","article-title":"The JAK attack: transforming the management of ulcerative colitis in India","volume":"24","author":"Singh","year":"2026","journal-title":"Intest Res"},{"key":"2026101518422828800_jjag147-B12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2036.2006.03156.x","article-title":"Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies","volume":"25","author":"Creed","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"2026101518422828800_jjag147-B13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/ecco-jcc\/jjy171","article-title":"ANP32E, a protein involved in steroid-refractoriness in ulcerative colitis, identified by a systems biology approach","volume":"13","author":"Lor\u00e9n","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026101518422828800_jjag147-B14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"2026101518422828800_jjag147-B15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/0140-6736(90)91521-b","article-title":"Preliminary report: cyclosporin in treatment of severe active ulcerative colitis","volume":"336","author":"Lichtiger","year":"1990","journal-title":"Lancet"},{"key":"2026101518422828800_jjag147-B16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gut.38.6.905","article-title":"Predicting outcome in severe ulcerative colitis","volume":"38","author":"Travis","year":"1996","journal-title":"Gut"},{"key":"2026101518422828800_jjag147-B17","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1177\/0962280215588241","article-title":"Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable","volume":"25","author":"Whitehead","year":"2016","journal-title":"Stat Methods Med Res"},{"key":"2026101518422828800_jjag147-B18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.fertnstert.2024.01.040","article-title":"A brief overview of pilot studies and their sample size justification","volume":"121","author":"Kunselman","year":"2024","journal-title":"Fertil Steril"},{"key":"2026101518422828800_jjag147-B19","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2026101518422828800_jjag147-B20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1208\/s12248-019-0362-6","article-title":"Modeling combined anti-inflammatory effects of dexamethasone and tofacitinib in arthritic rats","volume":"21","author":"Yu","year":"2019","journal-title":"AAPS J"},{"key":"2026101518422828800_jjag147-B21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11095-020-02827-7","article-title":"Interactions of tofacitinib and dexamethasone on lymphocyte proliferation","volume":"37","author":"Yu","year":"2020","journal-title":"Pharm Res"},{"key":"2026101518422828800_jjag147-B22","doi-asserted-by":"publisher","first-page":"20172","DOI":"10.1038\/s41598-026-50171-4","article-title":"Partial responders to intravenous corticosteroids at day 3 benefit from continued therapy in acute severe ulcerative colitis","volume":"16","author":"Singh","year":"2026","journal-title":"Sci Rep"},{"key":"2026101518422828800_jjag147-B23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.34172\/mejdd.2022.253","article-title":"Risk factors affecting 90-day readmission of patients with inflammatory bowel disease","volume":"14","author":"Ghahramani","year":"2022","journal-title":"Middle East J Dig Dis"},{"key":"2026101518422828800_jjag147-B24","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1007\/s10620-022-07490-z","article-title":"Delayed initiation of rescue therapy associated with increased length of stay in acute severe ulcerative colitis","volume":"67","author":"Caplan","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2026101518422828800_jjag147-B25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/apt.70246","article-title":"Azathioprine or tofacitinib as maintenance therapy in corticosteroid-responsive acute severe ulcerative colitis","volume":"62","author":"Singh","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026101518422828800_jjag147-B26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026101518422828800_jjag147-B27","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"J\u00e4rnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"2026101518422828800_jjag147-B28","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.dld.2008.03.014","article-title":"Colectomy rate in acute severe ulcerative colitis in the infliximab era","volume":"40","author":"Aratari","year":"2008","journal-title":"Dig Liver Dis."},{"key":"2026101518422828800_jjag147-B29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/gutjnl-2024-333281","article-title":"Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial","volume":"74","author":"Amiot","year":"2025","journal-title":"Gut"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/10\/jjag147\/71990378\/jjag147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/10\/jjag147\/71990378\/jjag147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:42:35Z","timestamp":1792104155000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag147\/8923691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag147","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10]]},"article-number":"jjag147"}}